Development of Thyroid Carcinoma During Treatment With Pembrolizumab in a Lung Cancer Patient.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 31846639.
- Also identified by DOI 10.1016/j.athoracsur.2019.10.059.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Pembrolizumab, a programmed death 1 inhibitor, has been shown to have clinically significant efficacy in different types of cancer, providing long-term survival benefit for patients with lung cancer. Herein, we report the development of a primary thyroid cancer in a lung cancer patient that was being treated with pembrolizumab. Primary thyroid malignancy (and not only metastatic disease or immunotherapy-induced thyroiditis) should be considered in patients with lung cancer being treated with immune checkpoint inhibitors who develop new incidental thyroid lesions on imaging studies.
Medical subject headings
- Antibodies, Monoclonal, Humanized
- Carcinoma, Non-Small-Cell Lung
- Immunotherapy
- Lung Neoplasms
- Thyroid Neoplasms